Keel Point’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.02M | Buy |
11,997
+1,090
| +10% | +$235K | 0.18% | 83 |
|
|
2026
Q1 | $2.37M | Sell |
10,907
-923
| -8% | -$205K | 0.16% | 92 |
|
|
2025
Q4 | $2.7M | Sell |
11,830
-38
| -0.3% | -$8.66K | 0.16% | 92 |
|
|
2025
Q3 | $2.75M | Sell |
11,868
-87
| -0.7% | -$17.7K | 0.17% | 92 |
|
|
2025
Q2 | $2.22M | Buy |
11,955
+476
| +4% | +$88.5K | 0.15% | 102 |
|
|
2025
Q1 | $2.41M | Buy |
11,479
+1,204
| +12% | +$234K | 0.19% | 93 |
|
|
2024
Q4 | $1.83M | Buy |
10,275
+633
| +7% | +$116K | 0.15% | 101 |
|
|
2024
Q3 | $1.9M | Buy |
9,642
+473
| +5% | +$88.3K | 0.16% | 98 |
|
|
2024
Q2 | $1.75M | Buy |
9,169
+2,925
| +47% | +$485K | 0.16% | 101 |
|
|
2024
Q1 | $1.14M | Buy |
6,244
+445
| +8% | +$76.7K | 0.12% | 120 |
|
|
2023
Q4 | $899K | Buy |
5,799
+280
| +5% | +$40.8K | 0.11% | 124 |
|
|
2023
Q3 | $823K | Buy |
5,519
+663
| +14% | +$97.3K | 0.11% | 119 |
|
|
2023
Q2 | $654K | Sell |
4,856
-406
| -8% | -$59.5K | 0.09% | 136 |
|
|
2023
Q1 | $839K | Buy |
5,262
+1,593
| +43% | +$244K | 0.12% | 121 |
|
|
2022
Q4 | $593K | Buy |
3,669
+663
| +22% | +$102K | 0.09% | 147 |
|
|
2022
Q3 | $404K | Buy |
3,006
+24
| +0.8% | +$3.44K | 0.07% | 157 |
|
|
2022
Q2 | $420K | Buy |
2,982
+448
| +18% | +$68.5K | 0.07% | 164 |
|
|
2022
Q1 | $411K | Buy |
2,534
+81
| +3% | +$11.8K | 0.06% | 172 |
|
|
2021
Q4 | $332K | Buy |
2,453
+178
| +8% | +$21K | 0.04% | 196 |
|
|
2021
Q3 | $245K | Sell |
2,275
-70
| -3% | -$8K | 0.03% | 226 |
|
|
2021
Q2 | $264K | Buy |
2,345
+2
| +0.1% | +$225 | 0.03% | 216 |
|
|
2021
Q1 | $254K | Buy |
2,343
+282
| +14% | +$30.2K | 0.02% | 226 |
|
|
2020
Q4 | $221K | Buy |
+2,061
| New | +$198K | 0.02% | 226 |
|
|
2019
Q1 | – | Sell |
-4,492
| Closed | -$414K | – | 192 |
|
|
2018
Q4 | $414K | Hold |
4,492
| – | – | 0.06% | 134 |
|
|
2018
Q3 | $425K | Buy |
4,492
+1
| +0% | +$95 | 0.05% | 115 |
|
|
2018
Q2 | $416K | Buy |
4,491
+46
| +1% | +$4.49K | 0.06% | 100 |
|
|
2018
Q1 | $421K | Sell |
4,445
-1,967
| -31% | -$216K | 0.06% | 101 |
|
|
2017
Q4 | $620K | Sell |
6,412
-900
| -12% | -$84.8K | 0.09% | 83 |
|
|
2017
Q3 | $650K | Sell |
7,312
-1,109
| -13% | -$84.4K | 0.1% | 80 |
|
|
2017
Q2 | $611K | Buy |
8,421
+220
| +3% | +$14.8K | 0.12% | 83 |
|
|
2017
Q1 | $534K | Sell |
8,201
-290
| -3% | -$18.2K | 0.11% | 88 |
|
|
2016
Q4 | $532K | Buy |
8,491
+1,107
| +15% | +$67.6K | 0.12% | 80 |
|
|
2016
Q3 | $466K | Buy |
7,384
+883
| +14% | +$57.2K | 0.18% | 83 |
|
|
2016
Q2 | $403K | Buy |
+6,501
| New | +$396K | 0.17% | 92 |
|
|
2016
Q1 | – | Sell |
-3,905
| Closed | -$231K | – | 126 |
|
|
2015
Q4 | $231K | Sell |
3,905
-728
| -16% | -$41.9K | 0.12% | 112 |
|
|
2015
Q3 | $252K | Buy |
4,633
+3
| +0.1% | +$195 | 0.14% | 89 |
|
|
2015
Q2 | $322K | Buy |
4,630
+109
| +2% | +$7.12K | 0.15% | 78 |
|
|
2015
Q1 | $265K | Buy |
+4,521
| New | +$273K | 0.13% | 80 |
|
Other funds holding ABBV
Keel Point's ABBV Position: Q2 2026 in Review
Keel Point increased its AbbVie (ABBV) stake by 10% in Q2 2026, buying an estimated $235K and bringing the position to 11,997 shares worth $3.02M. The position accounts for 0.18% of the portfolio, ranked #83.
Keel Point first reported a position in ABBV in Q1 2015 and has held it in 38 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Keel Point held 11,997 shares of AbbVie worth $3.02M as of Q2 2026.
- Keel Point bought 1,090 AbbVie shares in Q2 2026, an estimated $235K.
- AbbVie made up 0.18% of Keel Point's portfolio in Q2 2026, its #83 holding.
- Keel Point first reported a position in AbbVie in Q1 2015 and has held it in 38 quarters since.
- 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Keel Point's 13F filing for Q2 2026, filed 14 Aug 2026.